共 50 条
- [21] Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trialANNALS OF THE RHEUMATIC DISEASES, 2017, 76 (05) : 840 - 847Burmester, Gerd R.Lin, YongPatel, Rahulvan Adelsberg, JanetMangan, Erin K.Graham, Neil M. H.van Hoogstraten, HubertBauer, DeborahIgnacio Vargas, JuanLee, Eun Bong
- [22] Efficacy and safety of adalimumab in Chinese patients with moderate to severe plaque psoriasis: Results from a phase 3, randomized, placebo-controlled, double-blind StudyJOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2015, 72 (05) : AB232 - AB232Zhang, JianzhongGu, JunZheng, JieZheng, MinWang, GangGu, YihuaOkun, Martin
- [23] Efficacy and safety of the biosimilar ABP 501 compared with adalimumab in patients with moderate to severe rheumatoid arthritis: a randomised, double-blind, phase III equivalence studyANNALS OF THE RHEUMATIC DISEASES, 2017, 76 (10) : 1679 - 1687Cohen, StanleyGenovese, Mark C.Choy, ErnestPerez-Ruiz, FernandoMatsumoto, AlanPavelka, KarelPablos, Jose L.Rizzo, WarrenHrycaj, PawelZhang, NanShergy, WilliamKaur, Primal
- [24] Efficacy, safety of adalimumab versus methotrexate in pediatric patients with severe chronic plaque psoriasis: Results from the treatment withdrawal and double-blind retreatment periods of a phase 3 studyJOURNAL OF INVESTIGATIVE DERMATOLOGY, 2015, 135 : S16 - S16Phillip, SandraPierre-Dominique, Pierre-DominiqueLandells, IanUnnebrink, KristinaWilliams, David A.
- [25] Efficacy and safety of brodalumab in the Korean population for the treatment of moderate to severe plaque psoriasis: A randomized, phase III, double-blind, placebo-controlled studyJOURNAL OF DERMATOLOGY, 2021, 48 (06): : 807 - 817Seo, Seong JunShin, Bong SeokLee, Joo-HeungJeong, Haeyoun
- [26] Bimekizumab for the treatment of moderate-to-severe plaque psoriasis: efficacy, safety, pharmacokinetics, pharmacodynamics and transcriptomics from a phase IIa, randomized, double-blind multicentre studyBRITISH JOURNAL OF DERMATOLOGY, 2022, 186 (04) : 652 - 663Oliver, R.Krueger, J. G.Glatt, S.Vajjah, P.Mistry, C.Page, M.Edwards, H.Garcet, S.Li, X.Dizier, B.Maroof, A.Watling, M.el Baghdady, A.Baeten, D.Ionescu, L.Shaw, S.
- [27] The efficacy and safety of tofacitinib in Asian patients with moderate to severe chronic plaque psoriasis: A Phase 3, randomized, double-blind, placebo-controlled studyJOURNAL OF DERMATOLOGICAL SCIENCE, 2017, 88 (01) : 36 - 45Zhang, JianZhongTsai, Tsen-FangLee, Min-GeolZheng, MinWang, GangJin, HongZhongGu, JunLi, RuoYuLiu, QuanZhongChen, JinTu, CaiXiaQi, ChunMeiZhu, HuaPorts, William C.Crook, Tim
- [28] Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trialLANCET, 2019, 394 (10198): : 576 - 586Reich, KristianGooderham, MelindaThaci, DiamantCrowley, Jeffrey J.Ryan, CaitrionaKrueger, James G.Tsai, Tsen-FangFlack, MaryGu, YihuaWilliams, David A.Thompson, Elizabeth H. Z.Paul, Carle
- [29] A Phase IIIb, Multicentre, Randomised, Parallel-Group, Placebo-Controlled, Double-Blind Study to Investigate the Efficacy and Safety of OROS Hydromorphone in Subjects with Moderate-to-Severe Chronic Pain Induced by Osteoarthritis of the Hip or the KneePAIN RESEARCH AND TREATMENT, 2011, 2011Vojtassak, JozefVojtassak, JozefJacobs, AdamRynn, LeonieWaechter, SandraRicharz, Ute
- [30] Efficacy and safety of adalimumab in Chinese patients with moderate-to-severe plaque psoriasis: results from a phase 3, randomized, placebo-controlled, double-blind studyJOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2017, 31 (01) : 89 - 95Cai, L.Gu, J.Zheng, J.Zheng, M.Wang, G.Xi, L. -Y.Hao, F.Liu, X. -M.Sun, Q. -N.Wang, Y.Lai, W.Fang, H.Tu, Y. -T.Sun, Q.Chen, J.Gao, X. -H.Gu, Y.Teixeira, H. D.Zhang, J. -Z.Okun, M. M.